While Teva's quarterly figures aren't expected to be pretty due to the impact of generics on the company's multiple sclerosis drug Copaxone, management should update investors on the $40.5 billion purchase of Allergan 's generic drug business during the accompanying conference call. As a refresher, this massive deal was supposed to close in the first quarter of 2016, but was later pushed back after the U.S. Federal Trade Commission asked Teva to sell off certain products and pipeline assets for antitrust purposes.